SARS-COV-2 AND PATIENTS WITH ASTHMA

The current coronavirus disease 2019 (COVID-19) pandemic has had far-reaching health, economic and political consequences worldwide. Asthma is a non-communicable lung disease that affects approximately 300 million people globally. Since the pathophysiology of both of these conditions is centred on the respiratory tract, there was initial concern that individuals with asthma may be at higher risk of developing severe disease with poorer outcomes. In this article, several aspects pertaining to asthma and COVID-19, including the associated risk and outcomes, the use of nebulisers and the role of adjunctive anti-asthma/anti-allergy medications, are discussed.